{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McHugh A"],"funding":["Cancer Research UK","European Research Council"],"pagination":["20265-20281"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5945540"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(29)"],"pubmed_abstract":["Proteasome inhibitors have distinct properties and the biochemical consequences of suppressing ubiquitin E1 enzymes and the proteasome differ. We compared the effects of the proteasome inhibitors bortezomib, ixazomib and carfilzomib and the ubiquitin E1 enzyme inhibitor MLN7243/TAK-243 on cell viability and cell death in normal keratinocytes and cutaneous squamous cell carcinoma (cSCC) cell lines. The effects of both a pulse of treatment and more extended incubation were investigated. This is relevant to directly-delivered therapy (topical treatment/intratumoral injection) where the time of exposure can be controlled and a short exposure may better reflect systemically-delivered inhibitor pharmacokinetics. These agents can selectively kill cSCC cells but there are variations in the pattern"],"journal":["Oncotarget"],"pubmed_title":["Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity."],"pmcid":["PMC5945540"],"funding_grant_id":["13044","250170"],"pubmed_authors":["McHugh A","Leigh IM","Saville MK","Mellerio JE","Fernandes K","South AP","Proby CM","Salas-Alanis JC"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.","description":"Proteasome inhibitors have distinct properties and the biochemical consequences of suppressing ubiquitin E1 enzymes and the proteasome differ. We compared the effects of the proteasome inhibitors bortezomib, ixazomib and carfilzomib and the ubiquitin E1 enzyme inhibitor MLN7243/TAK-243 on cell viability and cell death in normal keratinocytes and cutaneous squamous cell carcinoma (cSCC) cell lines. The effects of both a pulse of treatment and more extended incubation were investigated. This is relevant to directly-delivered therapy (topical treatment/intratumoral injection) where the time of exposure can be controlled and a short exposure may better reflect systemically-delivered inhibitor pharmacokinetics. These agents can selectively kill cSCC cells but there are variations in the pattern","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Apr","modification":"2026-04-29T16:42:27.463Z","creation":"2019-03-26T23:40:51Z"},"accession":"S-EPMC5945540","cross_references":{"pubmed":["29755650"],"doi":["10.18632/oncotarget.24750"]}}